Kendall Au
Stock Analyst at RBC Capital
(1.46)
# 3,550
Out of 4,595 analysts
5
Total ratings
n/a
Success rate
-1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kendall Au
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintained: Buy | $90 | $83.45 | +7.85% | 1 | Jul 31, 2026 | |
| SYK Stryker | Reiterated: Buy | $420 | $325.70 | +28.95% | 1 | Jul 31, 2026 | |
| PEN Penumbra | Maintained: Hold | $374 | $321.19 | +16.44% | 1 | Jul 31, 2026 | |
| BSX Boston Scientific | Reiterated: Buy | $70 | $46.73 | +49.80% | 1 | Jul 29, 2026 | |
| GEHC GE HealthCare Technologies | Reiterated: Buy | $80 | $68.02 | +17.61% | 1 | Jul 29, 2026 |
DexCom
Jul 31, 2026
Maintained: Buy
Price Target: $90
Current: $83.45
Upside: +7.85%
Stryker
Jul 31, 2026
Reiterated: Buy
Price Target: $420
Current: $325.70
Upside: +28.95%
Penumbra
Jul 31, 2026
Maintained: Hold
Price Target: $374
Current: $321.19
Upside: +16.44%
Boston Scientific
Jul 29, 2026
Reiterated: Buy
Price Target: $70
Current: $46.73
Upside: +49.80%
GE HealthCare Technologies
Jul 29, 2026
Reiterated: Buy
Price Target: $80
Current: $68.02
Upside: +17.61%